Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Sells $67,650.00 in Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Scott Dreyer sold 2,255 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $30.00, for a total value of $67,650.00. Following the completion of the sale, the executive vice president now owns 124,421 shares of the company’s stock, valued at approximately $3,732,630. The trade was a 1.78 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Collegium Pharmaceutical Trading Up 0.3 %

Shares of Collegium Pharmaceutical stock opened at $29.93 on Friday. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical, Inc. has a 52 week low of $27.28 and a 52 week high of $42.29. The stock has a 50 day moving average price of $30.75 and a two-hundred day moving average price of $32.77. The stock has a market capitalization of $942.38 million, a PE ratio of 12.90 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The firm had revenue of $181.95 million during the quarter, compared to analysts’ expectations of $179.68 million. As a group, equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several institutional investors have recently bought and sold shares of COLL. New Age Alpha Advisors LLC bought a new stake in Collegium Pharmaceutical during the fourth quarter worth $40,000. TD Private Client Wealth LLC grew its holdings in Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after buying an additional 483 shares in the last quarter. KBC Group NV grew its holdings in Collegium Pharmaceutical by 72.5% during the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after buying an additional 982 shares in the last quarter. Virtus Fund Advisers LLC grew its holdings in Collegium Pharmaceutical by 30.5% during the fourth quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock worth $69,000 after buying an additional 565 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its holdings in Collegium Pharmaceutical by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after buying an additional 316 shares in the last quarter.

Wall Street Analyst Weigh In

COLL has been the subject of a number of research analyst reports. Piper Sandler lowered their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Tuesday, February 4th. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a report on Friday, January 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a report on Friday, January 10th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Collegium Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average price target of $43.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.